---
title: "Boris Peaker Reiterates Buy Rating on ELVN-001 with Unchanged $45 Price Target, Citing Strong Clinical Data and Strategic Positioning"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286152848.md"
description: "Boris Peaker of JonesTrading has reiterated a Buy rating on ELVN-001, maintaining a $45 price target due to strong clinical data and strategic positioning. The drug shows promising molecular response rates and tolerability in late-line CML patients. Peaker highlights ELVN-001's unique mechanism and efficacy compared to competitors, alongside the company's solid cash position. Guggenheim also initiated coverage with a Buy rating and a $80 price target. Peaker has a 20.3% average return and a 45.78% success rate on his stock recommendations."
datetime: "2026-05-12T20:25:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286152848.md)
  - [en](https://longbridge.com/en/news/286152848.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286152848.md)
---

# Boris Peaker Reiterates Buy Rating on ELVN-001 with Unchanged $45 Price Target, Citing Strong Clinical Data and Strategic Positioning

JonesTrading analyst Boris Peaker has maintained their bullish stance on ELVN stock, giving a Buy rating yesterday.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Boris Peaker has given his Buy rating due to a combination of factors, including encouraging clinical data for ELVN-001 in late-line CML patients who previously received Scemblix. The drug has demonstrated strong molecular response rates, durable responses over time, and a favorable tolerability profile, with only a modest discontinuation rate, supporting confidence in its therapeutic value.

Peaker also views ELVN-001’s ATP-binding pocket mechanism and efficacy in heavily pre-treated patients as differentiating advantages versus competing agents like TERN-701 and existing ATP inhibitors. Combined with the company’s solid cash position, clear strategic opportunity in the 2L/2L+ setting, and an unchanged $45 price target, these elements underpin his positive outlook and justify maintaining a Buy recommendation.

Peaker covers the Healthcare sector, focusing on stocks such as Relay Therapeutics, Enliven Therapeutics, and Nuvation Bio. According to TipRanks, Peaker has an average return of 20.3% and a 45.78% success rate on recommended stocks.

In another report released yesterday, Guggenheim also initiated coverage with a Buy rating on the stock with a $80.00 price target.

### Related Stocks

- [ELVN.US](https://longbridge.com/en/quote/ELVN.US.md)
- [RLAY.US](https://longbridge.com/en/quote/RLAY.US.md)
- [NUVB.US](https://longbridge.com/en/quote/NUVB.US.md)
- [NUVB+.US](https://longbridge.com/en/quote/NUVB+.US.md)

## Related News & Research

- [Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars](https://longbridge.com/en/news/271976921.md)
- [16:05 ETEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update](https://longbridge.com/en/news/285607145.md)
- [Lupin bets big on India's GLP-1 market & respiratory drugs](https://longbridge.com/en/news/287021542.md)
- [00:45 ETAraceli Biosciences Launches Endeavor® Live Cell for Ultra-High-Throughput Kinetic Imaging in AI-Driven Drug Discovery](https://longbridge.com/en/news/287006505.md)
- [Eli Lilly (LLY) Is the Face of the Obesity Boom. Has the Market Already Priced It In?](https://longbridge.com/en/news/286727957.md)